ResultsIQ

ResultsIQ › Latest results › Anuh Pharma Limited

Anuh Pharma Limited Q1 FY26 results deck summary

NSE: ANUHPHR · BSE: 506260

Results deck of 22 Aug 2025, summarised by AI from the filing.

Q1 FY26 operating revenue grew 35% to ₹186.48 cr, but EBITDA margin fell to 7.34% and PAT declined 12.7% to ₹8.30 cr.

Key takeaways

  1. Revenue growth Operating revenue grew 35% year-on-year to ₹186.48 cr from ₹137.91 cr, driven by customer reach and product portfolio.
  2. Margin outlook Management expects process, purchase and utility optimisation with higher-margin product sales to restore margins in coming quarters.
  3. Profitability decline PAT fell 12.7% to ₹8.30 cr from ₹9.51 cr, and EBITDA margin declined to 7.34% from 10.36%.
  4. Growth strategy Growth strategy relies on market expansion, new products and inorganic opportunities, with a steady growth rate of 15-16% per annum anticipated.
  5. Input costs Input cost pressures kept operating profit almost flat at ₹30.73 cr against ₹31.15 cr.

Original filing on BSE

Anuh Pharma Limited Q1 FY27 results

As filed: Revenue ₹194 cr (+4% year on year), EBITDA ₹16.3 cr (+48% year on year), PAT ₹11.4 cr (+43% year on year), EBITDA margin 8.4% (+249 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹202 cr (+2% year on year), EBITDA ₹19.9 cr (+5% year on year), PAT ₹11.7 cr (−3% year on year), EBITDA margin 9.8% (+24 bps). Score 35 of 100, Below trend. EBITDA margin rose 24 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 13% from last quarter. Share price after the results: −4.4% in 30 days (Nifty 500: +2.5%).
  • Q3 FY26: Revenue ₹197 cr (+23% year on year), EBITDA ₹16.8 cr (+20% year on year), PAT ₹13.5 cr (+35% year on year), EBITDA margin 8.5% (−23 bps). Score 68 of 100, Above trend. EBITDA margin fell 23 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −2.1% in 28 days (Nifty 500: −4.1%).
  • Q2 FY26: Revenue ₹186 cr, EBITDA ₹12.0 cr, PAT ₹8.0 cr, EBITDA margin 6.5%. Not scored. No result for the same quarter last year. Share price after the results: −4.3% in 28 days (Nifty 500: +1.3%).
  • Q1 FY26: Revenue ₹186 cr, EBITDA ₹11.0 cr, PAT ₹8.0 cr, EBITDA margin 5.9%. Not scored. No result for the same quarter last year. Share price after the results: −7.0% in 28 days (Nifty 500: +1.7%).
  • Q4 FY25: Revenue ₹198 cr, EBITDA ₹19.0 cr, PAT ₹12.0 cr, EBITDA margin 9.6%. Not scored. No result for the same quarter last year. Share price after the results: −0.4% in 28 days (Nifty 500: +1.1%).
  • Q3 FY25: Revenue ₹160 cr, EBITDA ₹14.0 cr, PAT ₹10.0 cr, EBITDA margin 8.8%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

Anuh Pharma Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.